Nuvation Bio (NYSE:NUVB) Price Target Raised to $21.00

Nuvation Bio (NYSE:NUVB) had its target price increased by HC Wainwright from $17.00 to $21.00 in a research note published on Monday, Marketbeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.30) EPS.

A number of other research firms have also issued reports on NUVB. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Nuvation Bio in a report on Thursday, July 23rd. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Zacks Research raised Nuvation Bio from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Friday, July 17th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Nuvation Bio in a research note on Wednesday, July 22nd. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.88.

Nuvation Bio Stock Down 1.6%

NUVB stock opened at $6.58 on Monday. Nuvation Bio has a fifty-two week low of $2.18 and a fifty-two week high of $9.75. The stock has a market cap of $2.29 billion, a PE ratio of -15.30 and a beta of 1.52. The firm’s 50-day simple moving average is $5.53 and its 200 day simple moving average is $5.24. The company has a quick ratio of 7.24, a current ratio of 7.44 and a debt-to-equity ratio of 0.15.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.04. The company had revenue of $83.23 million during the quarter, compared to analyst estimates of $66.22 million. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%. As a group, sell-side analysts predict that Nuvation Bio will post -0.38 EPS for the current year.

Insider Buying and Selling

In other news, insider Kerry Wentworth sold 63,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.02, for a total value of $379,260.00. Following the completion of the sale, the insider directly owned 53,000 shares in the company, valued at approximately $319,060. The trade was a 54.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Mashal acquired 25,000 shares of Nuvation Bio stock in a transaction dated Tuesday, June 9th. The stock was purchased at an average price of $4.73 per share, with a total value of $118,250.00. Following the completion of the purchase, the director directly owned 225,000 shares of the company’s stock, valued at $1,064,250. The trade was a 12.50% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 235,668 shares of company stock worth $1,419,495 over the last ninety days. Company insiders own 30.11% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Capricorn Fund Managers Ltd bought a new stake in Nuvation Bio during the fourth quarter valued at about $14,236,000. JPMorgan Chase & Co. grew its position in shares of Nuvation Bio by 472.8% in the third quarter. JPMorgan Chase & Co. now owns 675,600 shares of the company’s stock valued at $2,500,000 after purchasing an additional 557,656 shares during the last quarter. Ishara Investments LP bought a new position in shares of Nuvation Bio in the fourth quarter worth about $3,584,000. ACT Capital Management LLC acquired a new position in shares of Nuvation Bio during the 4th quarter worth about $5,470,000. Finally, Kornitzer Capital Management Inc. KS acquired a new position in shares of Nuvation Bio during the 1st quarter worth about $634,000. 61.67% of the stock is currently owned by institutional investors and hedge funds.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.